View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 5, 2020updated 12 Jul 2022 11:48am

Algernon gets FDA approval to trial Ifenprodil for Covid-19

Algernon Pharmaceuticals has obtained US Food and Drug Administration (FDA) clearance for a Phase IIb/III clinical trial of its NP-120 (Ifenprodil) as a potential treatment for Covid-19.

Algernon Pharmaceuticals has obtained US Food and Drug Administration (FDA) clearance for a Phase IIb/III clinical trial of its NP-120 (Ifenprodil) as a potential treatment for Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Ifenprodil is an antagonist of N-methyl-D-aspartate (NMDA) receptor. The drug is designed to selectively act on the NMDA-type subunit 2B (Glu2NB) and prevent glutamate signalling.

It is believed to be capable of mitigating the infiltration of neutrophils and T-cells into the lungs, where they can produce glutamate and cytokines, respectively. Cytokines can result in cytokine storm related to the loss of lung function and death reported in Covid-19 patients.

The multi-national, randomised, open-label Phase IIb/II trial will assess the safety and efficacy of the drug to treat hospitalised patients with confirmed Covid-19.

After obtaining local ethics approvals, the study will be started as a Phase IIb study in a total of 100 patients. If positive preliminary results are obtained, the study will advance directly from a Phase IIb into a Phase III trial.

The study results will help determine the number of patients required to demonstrate statistical significance in the Phase III trial. 

Participants will be given an existing standard of care or standard of care plus a 20mg Ifenprodil dose three times a day for two weeks. Various measures will be monitored, including mortality, blood oxygen levels, time in intensive care, and time to mechanical ventilation.

Algernon Pharmaceuticals CEO Christopher Moreau said: “We very much appreciated the timely responses that we have received from the US FDA since we first began working with the agency on our Covid-19 clinical trial programme.

“We have already begun the background work to start the Phase II trial in the US and other countries as soon as possible and we will update the market shortly on our planned timelines.”

For the Phase IIb/II trial, the company has already secured clearance in Canada and also filed for ethics approval in Australia.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena